Targeted

Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy

Contributing Editor With over 200,000 new cases and 40,000 deaths per year, breast cancer undoubtedly qualifies as one of Americas most serious health problems. Recently, efforts to develop early detection methods and more effective therapy have made important progress. This is particularly...

Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics

PHILADELPHIA, July 3, 2007 ? Researchers in Slovakia havebeen able to derive mesenchymal stem cells from human adipose, orfat, tissue and engineer them into “suicide genes” that seek out and destroy tumors like tiny homing missiles. This gene therapy approach is a novel way to attack smalltumor metastases that evade current detection techniques andtreatments, the researchers...

Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma

CHICAGO and REGENSBURG - June 21, 2007 - “In anaplasticastrocytoma, AP 12009 as a monotherapy is actually clearly superiorto temozolomide,” Prof. Albert Wong, M.D., StanfordUniversity, California, U.S.A. commented on the international PhaseIIb study with the TGF-beta 2-inhibitor AP 12009, under developmentby Antisense Pharma. Prof. Wong discussed the results of the studyin th...

Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference

BARCELONA, SPAIN and SEATTLE, WA -- (MARKET WIRE) -- June 14,2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) today isreporting data from the dose escalation arm of the ongoing PhaseI/II clinical study of tgAAC94 in patients with inflammatoryarthritis. Philip J. Mease, M.D., clinical professor at theUniversity of Washington School of Medicine, chief of rheumatologyclinical research a...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective atKilling CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab(Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), theNorwegian cancer therapeutics company, announces that a researchpaper showing the potential of its TH-1 technology for targetedcancer therapy has been published by the leading medical journal,...

ApoCell's Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented theresults of a study conducted by researchers at the University ofChicago and ApoCell at the 2007 annual meeting of the AmericanSociety of Clinical Oncology (ASCO) held in Chicago in early June.The study showed that ApoCell's advanced pharmacodynamic biomarkerassay technology provides reliable predictive data of clinicalrespon...

News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics

SAN MARINO, Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESSNEWSWIRE) -- Epeius Biotechnologies Corporation today announced thepublication of a historic landmark in medical oncology and adefinitive benchmark in the emerging field of cancer gene therapy.The first clinical report of its kind, Le Morte du Tumour --published in the June issue of the International Journal ofOncology, Vol.30,...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51

Other Presentations at AACR Highlight Progress in SuperGen'sOncology-Focused Pre-Clinical Pipeline LOS ANGELES, April 19, 2007 /PRNewswire-FirstCall/ -- SuperGenInc. today announced that MP470, its multi-targeted tyrosine kinaseinhibitor, suppresses the Rad51 protein, a critical component ofdouble- stranded DNA repair in cancer cells as part of a series ofpresentations at the 2007 America...

Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting

Data Indicate Significant Anti-Tumor Effects of Targeted, SystemicsiRNA Therapeutic at Doses Significantly Lower Than the Limits ofSafe Administrations in Rodent and Non-Human Primates PASADENA, Calif., April 16, 2007 /PRNewswire/ -- CalandoPharmaceuticals, a leading siRNA therapeutics company and amajority-owned subsidiary of Arrowhead Research Corporationpresented positive results of pr...

Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA

PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - ArrowheadResearch Corporation (NASDAQ:ARWR) announced today thatmajority-owned subsidiary Calando Pharmaceuticals has publishedresults in the Proceedings of the National Academy of Sciences(PNAS) of the first non-human primate study to use multiple,systemic dosing with Calando's lead siRNA therapeutic candidate. Calando is using its propri...

Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal

PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - CalandoPharmaceuticals, a leading siRNA therapeutics company and amajority-owned subsidiary of Arrowhead Research Corporation(NASDAQ: ARWR) announced the publication in the Proceedings of theNational Academy of Sciences (PNAS), the scientific journal of theNAS, of the first non-human primate study to use multiple, systemicdosing with Calando...

Data From Adherex's European Phase Ib/II Trial of ADH-1 to be Presented at International Symposium on Targeted Anticancer Therapies

RESEARCH TRIANGLE PARK, N.C., Mar 8, 2007 (CCNMatthews via COMTEXNews Network) -- Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), abiopharmaceutical company with a broad portfolio of oncologyproducts under development, today announced that Dr. AntonellaPerotti, MD, Istituto Nazionale dei Tumori Milano, SENDOFoundation, an investigator in Adherex's European Phase Ib/II studyof single-agent AD...